Researchers at the University of Sydney have been awarded $687,000 by the FDA to support a project titled, “Development of a laser-based testing platform for generic dry powder inhaler DPI evaluation and in-silico model validation,” the university said. The project is led by Hak-Kim Chan of the Sydney Pharmacy School and Agisilaos Kourmatzis of the School of Aerospace, Mechanical, and Mechatronic Engineering.
In 2020, aerosol characterization specialists Proveris Scientific announced that the company was working with Professors Chan and Kourmatzis on optical tomography techniques for real-time characterization of aerosolized particles.
Kourmatzis commented, “Our study aims to enhance in-vitro testing to help us better understand what is really going on in these complex systems. We will do this using more sophisticated data to drive the development of computational models that can fill in the gaps that we can’t address in the lab and by developing new optical and laser-based techniques that can offer new insights into this problem.”
Read the University of Sydney press release.
